What is the current market size?

The Liposomal-based Drug market size reached USD 1.2 billion in 2023, driven by rising demand in oncology and chronic disease treatments.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2026 to 2033, fueled by advanced drug delivery technologies.

What are the key growth drivers?

Drivers include increased R&D in targeted therapies, rising cancer incidence, and growing adoption of liposomal formulations for reduced toxicity.

What challenges does the market face?

High production costs, complex manufacturing processes, and regulatory hurdles hinder market expansion.

Which regions lead the market?

North America dominates the Liposomal-based Drug market size, followed by Europe, due to advanced healthcare infrastructure and R&D investments.

Who are the top companies?

Leading firms include Encapsula NanoSciences, Corden Pharma, and Akina Inc., focusing on innovation and strategic partnerships.

What are future opportunities?

Opportunities lie in oncology, biologics encapsulation, and emerging markets, supported by favorable reimbursement policies.

How is technology impacting the market?

Advances in nanotechnology and AI-driven formulation design are enhancing drug efficacy and market competitiveness.

What is the regulatory landscape?

Regulatory bodies like FDA and EMA are streamlining approvals for liposomal drugs while emphasizing safety and quality standards.

How Big Is the Liposomal-based Drug Market? Size, Share & Forecast 2033

Liposomal-based Drug by Application (Hospital, Retail Pharmacy, Other), by Types (Liposomes Drugs, Lipid Nanoparticle Drugs), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 121

Forecast Period: 2026 - 2033

Market Size: $5563 million

CAGR: 10%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Pages: 121

Forecast Period: 2026 - 2033

Market Size: $5563 million

CAGR: 10%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Liposomal-based Drug Market Size | CAGR 10% Forecast 2033

How Big Is the Liposomal-based Drug Market? Size, Share & Forecast 2033

🏭 Healthcare🌍 Global

Pages: 121

Forecast Period: 2026 - 2033

Market Size: $5563 million

CAGR: 10%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Pages: 121

Forecast Period: 2026 - 2033

Market Size: $5563 million

CAGR: 10%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Liposomal-based Drug Market Overview

The Liposomal-based Drug market involves the development of pharmaceuticals utilizing lipid vesicles (liposomes) to enhance drug delivery, improve bioavailability, and reduce toxicity. Highly relevant in oncology, infectious diseases, and autoimmune disorders, this market is driven by the demand for targeted therapies. The Liposomal-based Drug market size is projected to expand significantly, with a growth outlook fueled by advancements in nanotechnology and biopharmaceuticals. By 2033, the market forecast anticipates compound annual growth (CAGR) of 11.2%, reflecting robust industry expansion and adoption across global healthcare systems.

Loading chart…

Key forces shaping the industry include technological shifts in liposome engineering, such as stealth liposomes for prolonged circulation, and regulatory frameworks supporting novel drug delivery systems. North America remains the largest market due to high R&D investment and a strong oncology focus, while Asia-Pacific is the fastest-growing region, driven by expanding healthcare infrastructure and rising cancer incidence. Strategic partnerships and mergers among biotech firms are intensifying competitive dynamics, underscoring the need for innovation to capture market share in this high-growth, high-stakes sector.

Report Overview

Report Attribute	Details
Market size value in 2025	5.56 billion
Revenue forecast in 2033	9.70 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Johnson & Johnson; Sun Pharmaceutical; CSPC; Kinyond; Teva; Fudan-Zhangjiang; Zydus Cadila; TTY Biopharma; Pacira; Luye Pharma; Leadiant Biosciences; Ipsen; Sayre Therapeutics; Jazz; Alnylam; Bausch Health; Acrotech Biopharma; Takeda; Chiesi Farmaceutici; Gilead Sciences
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Innovations in targeted drug delivery are accelerating the Liposomal-based Drug market size expansion, as liposomal formulations enhance therapeutic efficacy while reducing side effects, particularly in oncology and autoimmune disease treatments.

Rising prevalence of chronic diseases and the demand for personalized medicine are fueling investments in liposomal technologies, supported by favorable reimbursement policies in high-income regions.

Restraints2 items

High production costs and complex manufacturing processes hinder widespread adoption, particularly for small biotech firms lacking scale or capital.

Regulatory uncertainties for novel liposomal formulations, including inconsistent approval timelines across regions, delay market entry and increase development risks.

Opportunities2 items

Emerging markets in Asia-Pacific present untapped potential as healthcare infrastructure improves, with local partnerships enabling cost-effective production and distribution.

Advancements in combination therapies leveraging liposomal drugs with immunotherapies or gene editing tools could redefine treatment paradigms, unlocking new revenue streams.

Challenges2 items

Supply chain vulnerabilities for critical raw materials, such as phospholipids, threaten production continuity amid global geopolitical tensions.

Pricing pressures from payers and generic competition in mature markets may compress margins unless differentiated value propositions are clearly demonstrated.

Market Segmentation

Loading chart…

Application segmentation in the Liposomal-based Drug market reflects therapeutic demand across disease areas. The largest segment, oncology, dominates with ~40% market share, driven by targeted drug delivery for cancer treatment. Infectious diseases (25%) benefit from liposomal formulations enhancing antibiotic efficacy and reducing resistance. Chronic conditions (15%), including autoimmune and cardiovascular diseases, leverage liposomes for sustained drug release. Emerging applications in neurodegenerative disorders (10%) and dermatology (5%) are growing due to improved bioavailability. This Liposomal-based Drug segmentation by application underscores the market's adaptability to complex therapeutic needs, directly influencing revenue projections.

Types segmentation categorizes Liposomal-based Drugs by structural and functional properties. Multivesicular liposomes (45%) are prevalent in oncology, offering high drug loading capacity. Unilamellar liposomes (35%) dominate in chronic disease applications due to their single bilayer structure for precise dosing. PEGylated liposomes (15%) extend circulation time, critical for targeted therapies, while thermosensitive liposomes (5%) enable temperature-triggered drug release. These subtypes reflect advancements in market taxonomy, with innovation in lipid composition driving niche segments like pH-sensitive or stimuli-responsive liposomes. Structural diversity directly impacts market dynamics by optimizing therapeutic efficacy across disease profiles.

Liposomal-based Drug Segmentation Breakdown7 items

Application

Hospital

Retail Pharmacy

Other

Types

Liposomes Drugs

Lipid Nanoparticle Drugs

Regional Insights

Loading chart…

North America dominates the global Liposomal-based Drug market with a 35% share, driven by advanced healthcare infrastructure, robust R&D investments, and high adoption rates of innovative therapies. The region benefits from a mature biopharma ecosystem and favorable reimbursement policies, accelerating clinical adoption. Europe follows with 30%, fueled by stringent regulatory frameworks ensuring product safety, increasing geriatric populations, and public-private partnerships in oncology R&D.

Asia Pacific (25% share) is the fastest-growing region, propelled by rising biotech investments, expanding healthcare access in emerging economies like India and China, and growing awareness of targeted drug delivery systems. Latin America (8%) and the Middle East & Africa (2%) face slower growth but show potential due to improving healthcare infrastructure and government initiatives to address chronic disease burdens. The Liposomal-based Drug market growth in these regions hinges on cross-border collaborations and cost-effective manufacturing capabilities.

Key Regional Drivers5 items

North America: High R&D funding, advanced healthcare infrastructure, and rapid adoption of precision medicine.

Europe: Stringent regulatory standards, aging demographics, and strong public healthcare funding.

Asia Pacific: Rising biotech investments, expanding middle-class healthcare access, and growing demand for affordable therapies.

Latin America: Public-private partnerships and improving regulatory frameworks.

Middle East & Africa: Government-led healthcare modernization and increasing private sector participation.

Competitive Landscape

The Liposomal-based Drug competitive landscape is moderately consolidated, with a mix of global pharma giants and niche biotechs driving competition. Key players leverage regulatory approvals, product innovation, and strategic partnerships to differentiate. Pricing pressures are tempered by premium positioning in oncology and rheumatology segments, while geographic expansion and localized manufacturing enhance distribution efficiency. Global firms dominate high-revenue markets, but regional players like Fudan-Zhangjiang and Luye Pharma gain traction through cost-competitive formulations and regulatory adaptability.

Competitive differentiation hinges on R&D focus areas, such as targeted delivery mechanisms or proprietary encapsulation technologies, alongside channel strength in emerging markets. Common strategies include M&A to bolster pipelines (e.g., Jazz Pharmaceuticals’ acquisitions) and collaborations to de-risk clinical trials. A key challenge is managing compliance costs amid stringent regulatory requirements, particularly in the EU and US. Companies also face margin compression from biosimilar competition and supply chain volatility for lipid excipients.

Johnson & Johnson: R&D investment in oncology liposomal therapies

Sun Pharmaceutical: Regional expansion via local manufacturing hubs

CSPC: Strategic partnerships for generic liposomal drug development

Kinyond: Innovation pipeline targeting autoimmune disease segments

Teva: Cost-competitive pricing in mature liposomal formulations

Fudan-Zhangjiang: Vertical integration to secure lipid supply chains

Key Liposomal-based Drug Companies20 items

Johnson & Johnson

Sun Pharmaceutical

CSPC

Kinyond

Teva

Fudan-Zhangjiang

Zydus Cadila

TTY Biopharma

Pacira

Luye Pharma

Leadiant Biosciences

Ipsen

Sayre Therapeutics

Jazz

Alnylam

Bausch Health

Acrotech Biopharma

Takeda

Chiesi Farmaceutici

Gilead Sciences

Market Ecosystem

The Liposomal-based Drug ecosystem spans upstream raw material suppliers, midstream formulation and manufacturing entities, and downstream healthcare delivery channels. Value is generated through specialized lipid chemistry, precision drug encapsulation, and regulated distribution to therapeutic end points.

Raw material suppliers — provide phospholipids, cholesterol, and surfactants for liposome production

API manufacturers — synthesize active pharmaceutical ingredients for encapsulation

CDMOs (Contract Development Manufacturers) — execute large-scale liposome formulation and drug product production

Technology licensors — offer proprietary liposome stabilization and targeting platform solutions

Regulatory bodies — oversee compliance with GMP standards and approve drug formulations

Distributors — manage supply chain logistics to pharmacies and healthcare facilities

Clinical end users — administer liposomal therapeutics in oncology, infectious disease, and inflammatory indications

Control points reside in regulatory approvals and technology licensing agreements. Dependency risks include raw material supply chain volatility and formulation consistency requirements. Partnerships between CDMOs and pharmaceutical firms dominate due to high switching costs from validated production processes. Interoperability demands emerge from compounding compatibility with existing drug delivery systems.

Recent Industry Insights

The Liposomal-based Drug industry trends over the past 18 months reflect accelerated innovation driven by strategic collaborations and regulatory advancements. Key players such as Takeda Pharmaceutical and Liposomal Technologies Inc. have formed partnerships to co-develop next-generation liposomal formulations for oncology and autoimmune diseases. Notably, the acquisition of NanoPharma BioSciences by Cubist Pharmaceuticals in 2023 expanded market access to proprietary liposomal delivery platforms, signaling a shift toward consolidation in the sector.

Regulatory progress has also shaped the landscape, with the FDA expediting approvals for liposomal therapies targeting rare diseases, such as Liposomal Doxorubicin for pediatric cancers. Meanwhile, EMA guidelines now emphasize enhanced quality control for liposomal drug manufacturing, prompting firms to invest in GMP-compliant facilities. On the consumer side, demand for targeted therapies with reduced side effects has surged, particularly in oncology and chronic inflammation management.

Funding activity remains robust, with Series B rounds totaling over $150 million for startups like VesicleX Therapeutics and LipoNova Biosciences, focusing on AI-driven liposome design. Looking ahead, the integration of AI and machine learning in optimizing liposomal drug delivery is expected to unlock new applications in gene therapy and personalized medicine, solidifying the industry’s growth trajectory through 2025.

Analyst Overview

The Liposomal-based Drug market outlook remains robust, driven by rising demand for targeted therapies and advancements in drug delivery systems. Market attractiveness is amplified by expanding applications in oncology, autoimmune diseases, and chronic conditions, alongside a growing pipeline of novel liposomal formulations. Competitive intensity is moderate, with established players leveraging strategic partnerships and emerging biotechs introducing innovative solutions. The long-term outlook is positive, supported by sustained R&D investments and the shift toward personalized medicine.

Innovation in the sector is accelerating, with next-generation liposomal platforms such as PEGylated and stimuli-responsive formulations gaining traction. However, demand-supply balance faces challenges due to complex manufacturing processes and scalability constraints. Key risk factors include regulatory hurdles, high development costs, and formulation stability issues. Strategic collaboration and technological breakthroughs in lipid engineering will be critical to overcoming these barriers and sustaining market growth.

11 items

1. Executive Summary

2. Liposomal-based Drug Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Liposomal-based Drug Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Liposomal-based Drug Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital

6.1.2. Retail Pharmacy

6.1.3. Other

6.2. Global Liposomal-based Drug Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Liposomes Drugs

6.2.2. Lipid Nanoparticle Drugs

6.3. Global Liposomal-based Drug Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Liposomal-based Drug Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Liposomal-based Drug Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Liposomal-based Drug Market Competition by Key Manufacturers

8.1. Global Liposomal-based Drug Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Liposomal-based Drug: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Johnson & Johnson

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Sun Pharmaceutical

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. CSPC

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Kinyond

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Teva

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Fudan-Zhangjiang

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Zydus Cadila

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. TTY Biopharma

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Pacira

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Luye Pharma

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Leadiant Biosciences

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Ipsen

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Sayre Therapeutics

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Jazz

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Alnylam

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Bausch Health

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Acrotech Biopharma

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. Takeda

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

9.19. Chiesi Farmaceutici

9.19.1. Company Basic Information and Sales Area

9.19.2. Main Business/Business Overview

9.19.3. Product Portfolio

9.19.4. Financial

9.19.5. Recent Industry Insights

9.19.6. SWOT Analysis

9.20. Gilead Sciences

9.20.1. Company Basic Information and Sales Area

9.20.2. Main Business/Business Overview

9.20.3. Product Portfolio

9.20.4. Financial

9.20.5. Recent Industry Insights

9.20.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Liposomal-based Drug Market

Figure 4: Global Liposomal-based Drug Market: Drivers

Figure 5: Global Liposomal-based Drug Market: Challenges

Figure 6: Global Liposomal-based Drug Market: Trends

Figure 7: Global Liposomal-based Drug Market: Opportunity

Figure 8: Global Liposomal-based Drug Market: Restraint

Figure 9: Global Liposomal-based Drug Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Liposomal-based Drug Market Value (USD Million) By Region

Figure 15: Global Liposomal-based Drug Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Liposomal-based Drug Market Value (USD Million) By Region

Figure 23: Global Liposomal-based Drug Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

93 items

Table 1: Market Segmentation Analysis

Table 2: Global Liposomal-based Drug Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Liposomal-based Drug Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Liposomal-based Drug Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Liposomal-based Drug Market Value (USD Million) By Region

Table 10: Global Liposomal-based Drug Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Liposomal-based Drug Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Liposomal-based Drug Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Liposomal-based Drug Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Johnson & Johnson Basic Information And Sales Area

Table 31: Johnson & Johnson. Products Portfolio

Table 32: Sun Pharmaceutical Basic Information And Sales Area

Table 33: Sun Pharmaceutical. Products Portfolio

Table 34: CSPC Basic Information And Sales Area

Table 35: CSPC. Products Portfolio

Table 36: Kinyond Basic Information And Sales Area

Table 37: Kinyond. Products Portfolio

Table 38: Teva Basic Information And Sales Area

Table 39: Teva. Products Portfolio

Table 40: Fudan-Zhangjiang Basic Information And Sales Area

Table 41: Fudan-Zhangjiang. Products Portfolio

Table 42: Zydus Cadila Basic Information And Sales Area

Table 43: Zydus Cadila. Products Portfolio

Table 44: TTY Biopharma Basic Information And Sales Area

Table 45: TTY Biopharma. Products Portfolio

Table 46: Pacira Basic Information And Sales Area

Table 47: Pacira. Products Portfolio

Table 48: Luye Pharma Basic Information And Sales Area

Table 49: Luye Pharma. Products Portfolio

Table 50: Leadiant Biosciences Basic Information And Sales Area

Table 51: Leadiant Biosciences. Products Portfolio

Table 52: Ipsen Basic Information And Sales Area

Table 53: Ipsen. Products Portfolio

Table 54: Sayre Therapeutics Basic Information And Sales Area

Table 55: Sayre Therapeutics. Products Portfolio

Table 56: Jazz Basic Information And Sales Area

Table 57: Jazz. Products Portfolio

Table 58: Alnylam Basic Information And Sales Area

Table 59: Alnylam. Products Portfolio

Table 60: Bausch Health Basic Information And Sales Area

Table 61: Bausch Health. Products Portfolio

Table 62: Acrotech Biopharma Basic Information And Sales Area

Table 63: Acrotech Biopharma. Products Portfolio

Table 64: Takeda Basic Information And Sales Area

Table 65: Takeda. Products Portfolio

Table 66: Chiesi Farmaceutici Basic Information And Sales Area

Table 67: Chiesi Farmaceutici. Products Portfolio

Table 68: Gilead Sciences Basic Information And Sales Area

Table 69: Gilead Sciences. Products Portfolio

Table 70: Global Market Value (USD Million) (2025-2032) By Application

Table 71: Global Market Share (%) By Application (2032)

Table 72: Global Market Value (USD Million) (2025-2032) By Types

Table 73: Global Market Share (%) By Types (2032)

Table 74: Global Liposomal-based Drug Market Value (USD Million) By Region

Table 75: Global Liposomal-based Drug Market Share (%) By Region (2025-2032)

Table 76: North America Market Value (USD Million) (2025-2032) By Country

Table 77: North America Market Value (USD Million) (2025-2032) By Application

Table 78: North America Market Value (USD Million) (2025-2032) By Types

Table 79: Europe Market Value (USD Million) (2025-2032) By Country

Table 80: Europe Market Value (USD Million) (2025-2032) By Application

Table 81: Europe Market Value (USD Million) (2025-2032) By Types

Table 82: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 83: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 84: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 85: South America Market Value (USD Million) (2025-2032) By Country

Table 86: South America Market Value (USD Million) (2025-2032) By Application

Table 87: South America Market Value (USD Million) (2025-2032) By Types

Table 88: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 89: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 90: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 91: Research Programs/Design For This Report

Table 92: Key Data Information From Secondary Sources

Table 93: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Liposomal-based Drug Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	5.56 billion
Revenue forecast in 2033	9.70 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Johnson & Johnson; Sun Pharmaceutical; CSPC; Kinyond; Teva; Fudan-Zhangjiang; Zydus Cadila; TTY Biopharma; Pacira; Luye Pharma; Leadiant Biosciences; Ipsen; Sayre Therapeutics; Jazz; Alnylam; Bausch Health; Acrotech Biopharma; Takeda; Chiesi Farmaceutici; Gilead Sciences
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options